Journal of Experimental & Clinical Cancer Research,
Journal Year:
2022,
Volume and Issue:
41(1)
Published: Dec. 29, 2022
Recently
genome-based
studies
revealed
that
the
abnormality
of
Hippo
signaling
is
pervasive
in
TNBC
and
played
important
role
cancer
progression.
RING
finger
protein
31
(RNF31)
comes
to
family
E3
ubiquitin
ligase.
Our
previously
published
have
RNF31
elevated
ER
positive
breast
via
activating
estrogen
suppressing
P53
pathway.We
used
several
cell
lines
xenograft
models
performed
immuno-blots,
QPCR,
vivo
investigate
function
progression.Here,
we
demonstrate
plays
tumor
suppressive
triple
negative
(TNBC).
depletion
increased
proliferation
migration
vitro
vitro.
coupled
with
global
genomic
expression
profiling
indicated
could
be
potential
target
for
exert
its
function.
Further
data
showed
increase
level
YAP
protein,
genes
lines,
while
clinical
illustrated
correlated
longer
relapse-free
survival
patients
reversely
level.
The
molecular
biology
assays
implicated
associate
facilitate
poly-ubiquitination
degradation
at
K76
sites.
Interestingly,
also
repress
PDL1
sensitive
immunotherapy
inhibiting
Hippo/YAP/PDL1
axis.Our
study
multi-faced
different
subtypes
malignancies,
activation
a
plausible
strategy
therapeutics.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: March 22, 2024
Abstract
Transforming
growth
factor
(TGF)-β
is
a
multifunctional
cytokine
expressed
by
almost
every
tissue
and
cell
type.
The
signal
transduction
of
TGF-β
can
stimulate
diverse
cellular
responses
particularly
critical
to
embryonic
development,
wound
healing,
homeostasis,
immune
homeostasis
in
health.
dysfunction
play
key
roles
many
diseases,
numerous
targeted
therapies
have
been
developed
rectify
its
pathogenic
activity.
In
the
past
decades,
large
number
studies
on
signaling
carried
out,
covering
broad
spectrum
topics
health,
disease,
therapeutics.
Thus,
comprehensive
overview
required
for
general
picture
this
field.
review,
we
retrace
research
history
introduce
molecular
mechanisms
regarding
biosynthesis,
activation,
transduction.
We
also
provide
deep
insights
into
functions
physiological
conditions
as
well
pathological
processes.
TGF-β-targeting
which
brought
fresh
hope
treatment
relevant
diseases
are
highlighted.
Through
summary
previous
knowledge
recent
updates,
review
aims
systematic
understanding
attract
more
attention
interest
area.
Molecular Cancer,
Journal Year:
2023,
Volume and Issue:
22(1)
Published: Sept. 2, 2023
Immunotherapy
has
recently
emerged
as
a
treatment
strategy
which
stimulates
the
human
immune
system
to
kill
tumor
cells.
Tumor
immunotherapy
is
based
on
editing,
enhances
antigenicity
of
cells
and
increases
tumoricidal
effect
It
also
suppresses
immunosuppressive
molecules,
activates
or
restores
function,
anti-tumor
responses,
inhibits
growth
f
cell.
This
offers
possibility
reducing
mortality
in
triple-negative
breast
cancer
(TNBC).Immunotherapy
approaches
for
TNBC
have
been
diversified
recent
years,
with
breakthroughs
this
entity.
Research
checkpoint
inhibitors
(ICIs)
made
it
possible
identify
different
molecular
subtypes
formulate
individualized
schedules.
review
highlights
unique
microenvironment
integrates
analyzes
advances
ICI
therapy.
discusses
strategies
combination
ICIs
chemotherapy,
radiation
therapy,
targeted
emerging
methods
such
nanotechnology,
ribonucleic
acid
vaccines,
gene
Currently,
numerous
ongoing
completed
clinical
trials
are
exploring
utilization
conjunction
existing
modalities
TNBC.
The
objective
these
investigations
assess
effectiveness
various
combined
determine
most
effective
regimens
patients
TNBC.This
provides
insights
into
used
overcome
drug
resistance
immunotherapy,
explores
directions
development
Journal for ImmunoTherapy of Cancer,
Journal Year:
2022,
Volume and Issue:
10(12), P. e005543 - e005543
Published: Dec. 1, 2022
Agents
blocking
programmed
cell
death
protein
1/programmed
death-ligand
1
(PD-1/PD-L1)
have
been
approved
for
triple-negative
breast
cancer
(TNBC).
However,
the
response
rate
of
anti-PD-1/PD-L1
is
still
unsatisfactory,
partly
due
to
immunosuppressive
factors
such
as
transforming
growth
factor-beta
(TGF-β).
In
our
previous
pilot
study,
bispecific
antibody
targeting
TGF-β
and
murine
PD-L1
(termed
YM101)
showed
potent
antitumor
effect.
this
work,
we
constructed
a
human
BiTP)
explored
effect
BiTP
in
TNBC.BiTP
was
developed
using
Check-BODYTM
platform.
The
binding
affinity
measured
by
surface
plasmon
resonance,
ELISA,
flow
cytometry.
bioactivity
assessed
Smad
NFAT
luciferase
reporter
assays,
immunofluorescence,
western
blotting,
superantigen
stimulation
assays.
activity
humanized
epithelial-mesenchymal
transition-6-hPDL1
4T1-hPDL1
TNBC
models.
Immunohistochemical
staining,
cytometry,
bulk
RNA-seq
were
used
investigate
on
immune
infiltration.BiTP
exhibited
high
dual
targets.
vitro
experiments
verified
that
effectively
counteracted
TGF-β-Smad
PD-L1-PD-1-NFAT
signaling.
vivo
animal
demonstrated
had
superior
relative
anti-PD-L1
anti-TGF-β
monotherapy.
Mechanistically,
decreased
collagen
deposition,
enhanced
CD8+
T
penetration,
increased
tumor-infiltrating
lymphocytes.
This
improved
tumor
microenvironment
contributed
BiTP.BiTP
retains
parent
antibodies'
bioactivity,
with
antibodies
TNBC.
Our
data
suggest
might
be
promising
agent
treatment.
Advanced Science,
Journal Year:
2023,
Volume and Issue:
10(18)
Published: April 23, 2023
Dendritic
cell
(DC)-based
cancer
immunotherapy
has
exhibited
remarkable
clinical
prospects
because
DCs
play
a
central
role
in
initiating
and
regulating
adaptive
immune
responses.
However,
the
application
of
traditional
DC-mediated
is
limited
due
to
insufficient
antigen
delivery,
inadequate
presentation,
high
levels
immunosuppression.
To
address
these
challenges,
engineered
biomaterials
have
been
exploited
enhance
immunotherapeutic
effects.
In
this
review,
vital
principal
components
that
can
effects
are
first
introduced.
The
parameters
considered
rational
design
biomaterials,
including
targeting
modifications,
size,
shape,
surface,
mechanical
properties,
which
affect
biomaterial
optimization
DC
functions,
further
summarized.
Moreover,
recent
applications
various
field
reviewed,
those
serve
as
component
delivery
platforms,
remodel
tumor
microenvironment,
synergistically
other
antitumor
therapies.
Overall,
present
review
comprehensively
systematically
summarizes
related
promotion
functions;
specifically
focuses
on
advances
designs
for
activation
eradicate
tumors.
challenges
opportunities
treatment
strategies
designed
amplify
via
discussed
with
aim
inspiring
translation
future
immunotherapies.
Chemical Society Reviews,
Journal Year:
2024,
Volume and Issue:
53(12), P. 6399 - 6444
Published: Jan. 1, 2024
This
review
highlights
recent
advances
in
immunological
nanomaterials
against
metastasis
and
summarizes
various
nanomaterial-mediated
immunotherapy
strategies.
Molecular Biomedicine,
Journal Year:
2022,
Volume and Issue:
3(1)
Published: Dec. 19, 2022
Abstract
The
transforming
growth
factor
beta
(TGF-β)
is
a
crucial
cytokine
that
get
increasing
concern
in
recent
years
to
treat
human
diseases.
This
signal
controls
multiple
cellular
responses
during
embryonic
development
and
tissue
homeostasis
through
canonical
and/or
noncanonical
signaling
pathways.
Dysregulated
TGF-β
plays
an
essential
role
contributing
fibrosis
via
promoting
the
extracellular
matrix
deposition,
tumor
progression
inducing
epithelial-to-mesenchymal
transition,
immunosuppression,
neovascularization
at
advanced
stage
of
cancer.
Besides,
dysregulation
TGF-beta
also
involves
other
diseases
including
anemia,
inflammatory
disease,
wound
healing
cardiovascular
disease
et
al.
Therefore,
this
proposed
be
promising
therapeutic
target
these
Recently,
strategies
targeting
signals
neutralizing
antibodies,
ligand
traps,
small-molecule
receptor
kinase
inhibitors
ligand–receptor
pathways,
antisense
oligonucleotides
disrupt
production
transcriptional
level,
vaccine
are
under
evaluation
safety
efficacy
for
forementioned
clinical
trials.
Here,
review,
we
firstly
summarized
biology
function
physiological
pathological
conditions,
elaborated
associated
transduction.
And
then,
analyzed
current
advances
preclinical
studies
transduction
Biomaterials Research,
Journal Year:
2022,
Volume and Issue:
26(1)
Published: Sept. 30, 2022
Combination
of
chemotherapy
and
immune
checkpoint
inhibitor
therapy
has
greatly
improved
the
anticancer
effect
on
multiple
malignancies.
However,
efficiency
triple-negative
breast
cancer
(TNBC)
is
limited,
since
most
patients
bear
"cold"
tumors
with
low
tumor
immunogenicity.
Doxorubicin
(DOX),
one
effective
agents,
can
induce
immunogenic
cell
death
(ICD)
thus
initiating
response.In
this
study,
to
maximize
ICD
induced
by
DOX,
chitosan
cell-penetrating
peptide
(R6F3)-modified
nanoparticles
(PNPs)
loaded
ginsenoside
Rg3
(Rg3)
were
fabricated
using
self-assembly
technique,
followed
co-encapsulation
DOX
based
thermo-sensitive
hydrogel.
Orthotopic
model
contralateral
established
observe
antitumor
efficacy
hydrogel
combined
anti-PD-L1
immunotherapy,
besides,
biocompatibility
was
also
evaluated
histopathological.Rg3-PNPs
strengthened
DOX.
Moreover,
co-loading
Rg3-PNPs
provoked
stronger
response
in
originally
nonimmunogenic
4T1
than
monotherapy.
Following
combination
PD-L1
blocking,
substantial
achieved
due
recruitment
memory
T
cells
decline
adaptive
enrichment.The
encapsulating
highly
permeable
provided
an
efficient
strategy
for
remodeling
immunosuppressive
microenvironment
converting
into
"hot"
tumors.
Advanced Functional Materials,
Journal Year:
2024,
Volume and Issue:
34(29)
Published: April 5, 2024
Abstract
Rapid
advances
in
nanotechnology
have
made
it
possible
to
combine
photothermal
therapy
(PTT)
with
immunotherapy,
enabling
activate
an
situ
vaccine
effect.
However,
this
effect
is
severely
impeded
by
low
antigen
presentation
level
and
highly
suppressive
tumor
immune
microenvironment
(immune
“cold”
tumors).
To
overcome
the
obstacles,
multifunctional
carrier‐free
nanoparticles
(FCDP‐NPs)
assembled
from
Fe
2+
,
toll‐like
receptor
9
agonist
(CpG),
cationic
lipid
(DOTAP)
agent
polydopamine
are
developed.
After
intratumoral
injection,
FCDP‐NPs
carrying
positive
charge
exposed
under
laser
irradiation,
which
can
capture
tumor‐associated
antigens
(TAAs)
generated
upon
post‐PTT
form
nanovaccines
(FCD‐NPs@TAAs).
The
further
promote
cross‐presentation
of
TAAs,
stimulate
adaptive
responses,
shape
“hot”
tumors.
As
a
result,
improve
survival
rates
elicit
durable
memory
that
remarkedly
prevents
metastasis,
illustrating
useful
platform
for
PTT
synergized
immunotherapy.
